The challenge for the next few years will be to individualize prostate cancer treatment and to determine whether or not a cancer will be lethal based on molecular characteristics at the time of diagnosis. In this view, the need for active treatment would represent a failure of any conservative approach.

Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?

Gandaglia G;MONTORSI , FRANCESCO;Briganti A.
2014

Abstract

The challenge for the next few years will be to individualize prostate cancer treatment and to determine whether or not a cancer will be lethal based on molecular characteristics at the time of diagnosis. In this view, the need for active treatment would represent a failure of any conservative approach.
Adenocarcinoma; Biomarkers, Tumor; Bone Neoplasms; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Watchful Waiting; Digital Rectal Examination; Urology; Medicine (all)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/4351
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact